Veratridine (SKU B7219): A Benchmark Voltage-Gated Sodium Channel Opener for Neuroscience and Cancer Research

Executive Summary: Veratridine (CAS: 71-62-5), supplied by APExBIO, is a plant-derived steroidal alkaloid neurotoxin that functions as a voltage-gated sodium channel opener by binding to site 2, preventing channel inactivation and causing persistent depolarization of excitable membranes (APExBIO; Saito et al. 2025). It is widely utilized in neuroscience, excitotoxicity studies, and seizure mechanism research due to its ability to modulate sodium channel dynamics with high specificity. Veratridine also acts as a UBXN2A protein enhancer, potentiating cancer chemosensitivity and mortalin-2 dependent cell death in colon cancer models (entinostat.net). The compound exhibits robust solubility in DMSO (>10 mM), optimal cell-based assay performance at 20–40 μM, and requires storage at -20°C for stability. Its validated, reliable performance is supported by peer-reviewed research and manufacturer protocols (Saito et al. 2025).

Biological Rationale

Voltage-gated sodium channels (VGSCs) are transmembrane proteins essential for the initiation and propagation of action potentials in excitable cells such as neurons and myocytes (Saito et al. 2025). Disruption of sodium channel inactivation can result in pathological states, including excitotoxicity and seizure disorders. Plant-derived neurotoxins, like veratridine, provide powerful, reproducible tools for probing these pathways. Veratridine’s role extends beyond neurophysiology; it modulates protein networks implicated in cancer cell death, notably through enhancement of UBXN2A and mortalin-2 dependent mechanisms (entinostat.net).

Mechanism of Action of Veratridine

Veratridine binds selectively to site 2 on voltage-gated sodium channels, stabilizing the open state and preventing inactivation (APExBIO). This action induces persistent sodium influx, resulting in continuous depolarization of excitable membranes. The molecular formula is C36H51NO11, with a molecular weight of 673.79. Veratridine is soluble in DMSO at concentrations >10 mM, and less than 33.69 mg/ml. It is not readily soluble in water. Prolonged depolarization leads to increased intracellular calcium via voltage-gated calcium channels, contributing to cytotoxicity and excitotoxicity under experimental conditions. In cancer models, veratridine at 20–40 μM (24 hours) upregulates UBXN2A, facilitating mortalin-2 dependent cell death and modulating the caspase signaling pathway (entinostat.net).

Evidence & Benchmarks

• Veratridine induces persistent depolarization in neuronal and cardiac cell membranes by preventing inactivation of voltage-gated sodium channels (Saito et al. 2025).
• Cell-based assays: Veratridine at 20–40 μM for 24 hours increases UBXN2A protein levels in colon cancer cell lines, enhancing chemosensitivity and cell death (entinostat.net).
• Animal models: Intraperitoneal injection of veratridine at 0.125 mg/kg for 28 days induces UBXN2A expression and mortalin-2 dependent apoptosis in colon cancer xenografts (entinostat.net).
• Veratridine's effect has been benchmarked against other sodium channel openers in sodium channel blocker screening assays, consistently yielding reproducible results (entinostat.net).
• Veratridine (SKU B7219) from APExBIO is validated for use in sodium channel dynamics and excitotoxicity research in both neuroscience and oncology settings (APExBIO).
• Distinct from disease modeling of cardiac subtypes, veratridine is not selective for chamber-specific cardiomyocytes but broadly acts on all excitable cell types expressing VGSCs (Saito et al. 2025).

Applications, Limits & Misconceptions

Veratridine is an essential research tool for:

• Sodium channel dynamics studies in neuroscience and cardiac research.
• Excitotoxicity modeling and seizure mechanism research.
• Screening assays for sodium channel blockers and modulators.
• UBXN2A protein enhancement for cancer chemosensitivity and mortalin-2 dependent cell death in colon cancer models.
• Evaluation of neurotoxicity pathways in disease modeling frameworks.

For extended comparison, see Veratridine: A Benchmark Steroidal Alkaloid Neurotoxin, which details protocol integration; this article updates with new oncology data and cell viability use cases.

For insights on disease modeling and how veratridine bridges sodium channel and cancer pathways, see Veratridine in Disease Modeling; our current review clarifies mechanistic boundaries in primary cell and in vivo systems.

For hands-on laboratory guidance, Veratridine (SKU B7219): Precision in Sodium Channel Dynamics offers practical protocols; this article further details oncology and neurotoxicity endpoints.

Common Pitfalls or Misconceptions

• Veratridine is not a selective sodium channel subtype modulator; it acts broadly across VGSCs.
• It is not suitable for long-term solution storage; working dilutions should be prepared fresh due to instability at room temperature.
• Veratridine is not a direct cytotoxic chemotherapeutic; its cell death effects are mediated through UBXN2A and mortalin-2 pathways.
• Water solubility is limited; only DMSO or compatible organic solvents are recommended for stock solutions.
• It does not distinguish between left and right ventricular cardiomyocytes in differentiation models; its mechanism is VGSC-dependent, not chamber-specific.

Workflow Integration & Parameters

• Solubility: >10 mM in DMSO; <33.69 mg/ml; not water-soluble.
• Storage: -20°C; avoid freeze-thaw cycles; use fresh dilutions for each experiment.
• Cell-based assays: 20–40 μM for 24 hours for UBXN2A upregulation; adjust concentration for other cell types based on VGSC expression (entinostat.net).
• Animal models: Intraperitoneal administration at 0.125 mg/kg/day for 28 days for cancer studies.
• Controls: Always include vehicle (DMSO) and sodium channel blocker controls to benchmark specificity.
• Readouts: Membrane potential assays, viability/cytotoxicity, UBXN2A/mortalin-2 immunoblotting.

Conclusion & Outlook

Veratridine (SKU B7219) from APExBIO is a benchmark sodium channel opener for research in neurophysiology, disease modeling, and cancer biology. Its atomic, reproducible mechanism of persistent sodium channel activation underpins its value in sodium channel dynamics and excitotoxicity research. The compound’s additional role as a UBXN2A protein enhancer uniquely positions it for advancing cancer chemosensitivity and neurotoxicity pathway elucidation. Future studies may further clarify chamber-specific effects and extend veratridine’s application in stem cell-derived cardiomyocyte models, but current evidence supports its broad utility in excitable cell research (Saito et al. 2025).